ArticleWorld journal of surgery2026
Mortality Benefit of Tranexamic Acid for Hemorrhage With Concurrent Traumatic Brain Injury: Outcomes From a Prospective Cohort Study in a High-Trauma, Prolonged Care Setting.
Article in World journal of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundTraumatic brain injury (TBI) and hemorrhage are leading causes of trauma death and disability worldwide. The concurrence of hemorrhage and brain injury carries a two-fold increase in mortality and clinical management of patients with concurrent TBI and hemorrhage is challenging. Tranexamic acid (TXA) has been shown to reduce mortality from hemorrhage and TBI independently, however there is sparse evidence on the potential benefit of TXA in patients with both non-head hemorrhage and TBI.
methodsWe conducted a secondary database analysis of EpiC, a multicenter, prospective cohort of trauma patients in South Africa. We compared the morbidity and mortality of patients experiencing both non-head hemorrhage and TBI who received TXA within 3-h post-injury versus similarly injured patients who did not receive TXA. Inverse probability treatment weighting (IPTW) was implemented followed by a multivariable logistic regression to evaluate 7-day mortality. Secondary outcomes included the worst 7-day sequential organ failure assessment (SOFA) and neurologic recovery assessed by Glasgow Outcomes Score Extended (GOSE).
resultsA total of 656 patients were included in the analysis. 132 (20%) received TXA within 3 h and 544 (80%) did not. For the primary outcome of 7-day mortality, treatment with TXA was associated with a 22% reduction in odds of death (mOR, 0.78, 95% CI, 0.62-0.98). TXA-treated patients had significant lower odds of SOFA > 4 or death (mOR, 0.71; 95%CI, 0.53-0.95) and non-significantly reduced odds of poor functional status at 3 months (GOSE < 7 or death) (mOR, 0.89; 95% CI, 0.68-1.18). Treatment with TXA within 2 h was associated with a 27% reduction in odds of 7-day mortality (mOR, 0.73; 95%CI, 0.61-0.86).
conclusionsIn this study, the administration of TXA within 3 h to patients with concurrent hemorrhage and TBI was associated with a 22% reduction in mortality at 7 days. The mortality benefit was slightly larger when TXA was given within 2 h. TXA treatment was also associated with lower risk of organ failure. These results support a growing body of evidence that TXA is an effective intervention to reduce mortality and morbidity after traumatic injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.